AxoGen delivered strong Q3 2025 results with revenue reaching $60.1 million, a 23.5% year-over-year growth, driven by robust demand across all nerve repair target markets.

• Q3 sales increased to $60.1 million, with double-digit growth in extremities, oral maxillofacial, and breast markets.
• High potential accounts contributed approximately 64% of revenue growth year-to-date, despite a transition phase affecting growth metrics.
• Strong surgeon adoption of the AxoGen nerve care algorithm, particularly in mandible reconstruction and breast resensation procedures.
• Successful completion of the hiring plan for commercial expansion, particularly in the breast resensation sales force.
• Anticipation of BLA approval for Avance Nerve Graft in December 2025, expected to enhance market positioning.